



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. INNOVATE. DEBATE. COMMUNICATE.

Facilitating Debate, Fostering Innovation,
Accelerating Access to the Best Treatments
for All Cancer Patients

 info@cddf.org

 www.cddf.org

◎ WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in **Belgium** that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in **cancer drug development**.

◎ OUR MISSION

The CDDF's mission is to **provide a trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate, and communication, fostering innovation** to **accelerate access to new (or the best) treatments** for all patients.

◎ HOW WE ADVANCE OUR MISSION

- ▶ The CDDF provides a **non-competitive, non-commercial platform** for **multi-stakeholder discussions** and **collaboration**.
- ▶ The CDDF **brings together all actors** in the oncology community such as **academia, the healthcare industry, regulatory authorities, health technology assessment (HTA) bodies, policymakers, and patient advocacy groups**.
- ▶ The CDDF **stimulates advancement and innovation** in the field through **scientific debate** and **open discussion**.

INITIATIVES

Since 2001, the Cancer Drug Development Forum (CDDF) has served as a **trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate and communication**, fostering innovation to **accelerate access to new treatments for patients**.

The CDDF champions progress by hosting **dynamic conferences, workshops, conferences, webinars, and projects** that bring together stakeholders involved in oncology. In a **neutral, non-competitive environment**, we foster **productive dialogue and open, respectful interactions** in collaboration with the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and regulators from Europe and worldwide, alongside with academic researchers, pharmaceutical companies, HTA bodies, and patient advocates. Together, we **accelerate breakthroughs** and **access to effective treatments for all patients**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

As a key part of the effort, the CDDF holds its **Annual Conference** that gathers key stakeholders and experts to address **challenges and opportunities in oncology drug development**. This interactive three-day meeting features plenary lectures with moderated discussions, offering multistakeholder perspectives and unique networking opportunities.

In addition to the Conference, the CDDF organizes **workshops, webinars and EU-level projects** to facilitate multi-stakeholder collaboration on **topical issues in the field of oncology**. The **responsive nature** of the CDDF platform enables the oncology community to initiate **timely conversations to reflect current and pressing needs**. We continue pioneering progress through upcoming programs, which explore the impact of digital AI approaches in discovery research and global and EU regulatory landscapes.

Through the **publication of white papers**, the CDDF goes the extra mile by **translating its meeting outcomes into actionable insights**, driving incremental, significant shifts in oncology.

We believe that **continued dialogue and active collaboration** are key to improving cancer treatments and accelerating patient access. We welcome all our stakeholders to join us in advancing this mission and making their voices heard.



**CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAs, THE HEALTHCARE
INDUSTRY, ACADEMICS, AND
PATIENT ADVOCATES TO
COLLABORATE**

**INCLUSIVE &
COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT**

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors, elected for three-year terms, dedicated to accelerating and optimizing cancer drug development and patient access. The board comprises distinguished individuals, including a patient advocate, pre-clinical and clinical investigators, medical oncologists, a pediatrician, and regulatory scientists, representing diverse perspectives within the drug development process.

These committed members bring vast experience from clinical, patient advocacy, industry and regulatory settings, ensuring the CDDF effectively functions as a neutral, non-competitive platform for all stakeholders involved in cancer drug development.

© CDDF BOARD OF DIRECTORS



**Mark
Lawler**

Chairperson



**Ruth
Plummer**

Managing
Director



**Stefan
Symeonides**

Vice-Chairperson



**Axel
Glasmacher**

Treasurer



**Jaap
Verweij**



**Rosa
Giuliani**



**Christian
Schneider**



**Fergus
Sweeney**



**Agnès
Saint-Raymond**



**Jana
Pelouchova**

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



**Thierry
Coppens**
Director of
Operations



**Giorgia
Campagnano**
Event Manager



**Shannon
Adeux**
Event Coordinator



**Hyunmin
Park**
Community &
Communication
Coordinator



CDDF ACTIVITIES 2026

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2026

Cancer Clinical Research in a Changing Global Environment

9-11 February 2026
Ghent, BE



- [Executive summary](#)
- [Recordings/slides*](#)

CDDF Cancer Drug Development Forum

AAADV Accelerating Anticancer Agent Development and Validation

MULTI-STAKEHOLDER WORKSHOP

Challenges in the Landscape of a Global Development Strategy, including patient access

30 - 31 March 2026
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides](#)
- White paper (available soon)

CDDF Cancer Drug Development Forum

EORTC European Organisation for Research and Treatment of Cancer
The future of cancer therapy

CDDF & EORTC JOINT WORKSHOP

Health Technology Assessment in Cancer Drug Development

5 - 6 October 2026
Brussels, BE (hybrid)



- [Workshop programme](#)
- [Registration](#)



**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: <https://cddf.org/member-access/>*

CDDF ACTIVITIES 2026

CDDF LIVE WEBINARS



LIVE WEBINAR

CDDF Live Webinar series – AI and Big Data AI in Drug Development: Use of AI in clinical trials

Dr. James Gulley (NIH)

12 May 2026
16:00-17:00 CET, Online



- [Key takeaways](#)

- [Recording/slides](#)



LIVE WEBINAR

CDDF Live Webinar series – AI and Big Data AI in Drug Development: transparency and risk assessment

Dr. Weida Tong (FDA)

16 June 2026
16:00-17:00 CET, Online



- [Key takeaways](#)

- [Recording/slides](#)



LIVE WEBINAR

"Compassionate Use and EAP for Cancer Drugs – From Fragmentation to a Common Framework in Europe under the New Legislation"

**Ramona Reichenbach (Novartis)
François Houjé (Eurordis)**

26 October 2026
16:00-17:00 CET, Online



- [Webinar outline](#)

- [Registration](#)

Webinars in the Planning Stage

- CDDF Diversity Initiative paper
- Learning from “facilitating and accelerating strategic clinical trials in the EU” **pilot FAST EU**

CDDF ACTIVITIES 2027

● MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2027

**How can we
accelerate cancer
drug development
and access for EU
patients ?**

8-10 February 2027
Antwerp, Belgium



CDDF & AAADV JOINT WORKSHOP

**Innovation in Acquisition
and Analysis of
Real-World Data
to support Clinical
Decision-Making**

19 - 20 April 2027
Brussels, BE (hybrid)



Multi-Stakeholder Workshop

- Date: 15-16 November 2027
- Location: Brussels (BE)
- Topic: TBC



More details will be available soon via the CDDF website

MEETING OUTCOMES 2025

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2025

Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials

3-5 February 2025
Noordwijk aan Zee, NL



- [Executive summary](#)
- [Recordings/slides](#)
- [White paper: Challenges and Potential Solutions to Advance Global Cancer Drug Development](#) (Therapeutic Innovation & Regulatory Science, March 2026)

CDDF
Cancer Drug Development Forum

MULTI-STAKEHOLDER WORKSHOP

New Modalities in Cancer Drug Development

31 March - 1 April 2025
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides*](#)
- White paper (available soon)

CDDF
Cancer Drug Development Forum

MULTI-STAKEHOLDER WORKSHOP

Enabling smarter clinical trials to optimise patient care

DEPLOYING DATA TO DESIGN AND DELIVER BETTER TRIALS

17 - 18 November 2025
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides*](#)
- White paper (available soon)



**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: <https://cddf.org/member-access/>*

MEETING OUTCOMES 2025

LIVE WEBINARS



LIVE WEBINAR

EU HTA Regulation

Michael Berntgen (EMA)
Niklas Hedberg (TLV)
Vanessa Schaub (Roche)

12 March 2025
17:00-18:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR

Using AI in assessing cancer treatment response on imaging: Project Data Sphere

Sean Khozin (Project Data Sphere, US)
Christopher Medberry (J&J, US)

23 April 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES:
Bayesian Framework

Bayesian Approaches in Oncology Drug Development: Introduction and Motivations

Purvi Prajapati (Eli Lilly)
Natalia Muhlemann (Cytel)

14 May 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES
AI and Big Data AI in drug development

Transformation of future clinical trials using AI-enhanced imaging biomarkers

Johannes Haubold (University of Essen)
Sasa Grbic (Siemens Healthineers)

18 September 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR

Long term outcomes of in utero exposure to cytotoxic therapy: is involving pregnant patients an absolute no-go in cancer drug development?

Frédéric Amant (UZ Leuven)

4 December 2025
16:00-17:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES: ACT EU

ACT EU: Collaborating with stakeholders to define priorities for clinical trials and working collectively to address them

Marianne Lunzer (Austrian Medicines Agency)
Laura Pioppo (EMA)


15 December 2025
16:00-17:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



CDDF INDUSTRY MEMBERS PLATFORM



WHAT IS THE CDDF INDUSTRY MEMBERS' PLATFORM?

The CDDF Industry Members' Platform is composed of large and SME members from the healthcare industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Members' Platform acts as an advisory body within the CDDF. It supports the association in compliance with all relevant regulations in a manner consistent with the non-competitive, non-commercial platform that the CDDF offers to all stakeholders.

WHY JOIN THE CDDF INDUSTRY MEMBERS' PLATFORM?



Stimulate advancement in oncology treatment and delivery

Identify and overcome challenges in the development of cancer drugs



Improve product time to market for new treatments

CONTRIBUTE TO THE **DEVELOPMENT OF
CANCER DRUGS AND TREATMENTS**



BECOME A MEMBER OF THE CDDF



INDUSTRY MEMBER BENEFITS

1

Unique Platform for Multi-Stakeholder Discussions

Access to the CDDF Industry Members' Platform to join members in addressing challenges in cancer drug development from a multi-stakeholder perspective



2

Complimentary Registration

Complimentary registration for in-person participants at every CDDF hybrid event (*one for small businesses, two for medium-sized enterprises and four for large healthcare companies*).



3

Livestream Access

Livestream access to all CDDF conferences, workshops and webinars.



4

Early Access to Digital Content

Early access to digital content from the CDDF's conference, workshops and webinars before public release.





BECOME A MEMBER OF THE CDDF



INDUSTRY MEMBER BENEFITS

5

Professional Contribution

Professional contribution to CDDF's scientific programme and the chance to collaborate with various stakeholders on developing content for CDDF meetings.



6

Access to a Reputable Oncology Network

Access to a reputable oncology network and opportunities to connect informally with representatives from academia, regulatory authorities, HTAs, and patient groups.



CDDF BREAKS DOWN SILOS
IN THE ONCOLOGY COMMUNITY AND
FACILIATES OPEN, MEANINGFUL DIALOGUE
AMONG ALL STAKEHOLDERS



CDDF INDUSTRY MEMBERSHIP PACKAGES



	Start-up or small business	Medium-sized enterprise	Large healthcare company
Criteria	No oncology product on the market <u>and</u> Revenues ≤ € 50 million	Either low revenues <u>and</u> at least one oncology product on the market or medium or large revenues <u>and</u> no oncology product on the market	At least one oncology product on the market <u>and</u> Revenues ≥ € 1 billion
Membership fee 2027 *	€ 8,400	€ 21,625	€ 48,175

*The membership fee is subject to an annual adjustment in line with the Belgian consumer price index for the previous year. Members are notified of fee inflation in September.



BENEFITS

Access the CDDF Industry Members Platform	✓	✓	✓
Free registration for every CDDF event	1	2	4
Livestream access to CDDF workshops and conference	5	15	Unlimited
Early access to digital content from the CDDF discussions before public release	5	15	Unlimited
Contribution to CDDF's scientific programme and collaboration with multi-stakeholders	✓	✓	✓



COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS

 info@cddf.org

 www.cddf.org

 [@cddf_eu](https://twitter.com/cddf_eu)

 [The Cancer Drug Development Forum \(CDDF\)](https://www.linkedin.com/company/cddf/)

 Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

 The CDDF is a non-profit association in the register of legal entities at the French
Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752